
InflaRx (IFRX) Stock Forecast & Price Target
InflaRx (IFRX) Analyst Ratings
Bulls say
InflaRx NV has received marketing authorization from the European Commission for Gohibic (vilobelimab) to treat adult patients with SARS-CoV-2-induced acute respiratory distress syndrome (ARDS), demonstrating significant clinical efficacy with a 23.9% relative reduction in 28-day all-cause mortality compared to placebo. The treatment has shown a high rate of complete resolution of dT and has maintained a favorable safety profile across various doses, indicating its potential as a key therapeutic option in a critical health crisis. The company’s proprietary anti-C5a/C5aR technology underpins its innovative approach to treating inflammatory diseases, contributing to a solid foundation for future growth and development within the biopharmaceutical sector.
Bears say
InflaRx NV's stock outlook is negatively impacted by concerns regarding its dependence on clinical trial outcomes, as the maximum HiSCR rate for its treatment Gohibic is only marginally higher than that of the placebo, suggesting limited efficacy. Additionally, while the company is exploring partnership and distribution options in Europe, these moves are not projected to significantly alleviate cash burn rates, indicating ongoing financial strain. Overall, the modest clinical results coupled with sustained cash consumption heighten the risk profile of InflaRx's business model.
This aggregate rating is based on analysts' research of InflaRx and is not a guaranteed prediction by Public.com or investment advice.
InflaRx (IFRX) Analyst Forecast & Price Prediction
Start investing in InflaRx (IFRX)
Order type
Buy in
Order amount
Est. shares
0 shares